Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 322,
Modbury North,
South Australia 5092

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 242KB)
Why become a member?

Low-dose naltrexone linked to reduction in pain in Fibromyalgia

Monday 1 April 2013

 

From Monthly Prescribing Reference:

 

Monthly Prescribing ReferenceNaltrexone Linked to Reduction in Pain in Fibromyalgia

February 12, 2013

(HealthDay News) – Low-dose naltrexone treatment is associated with significant reductions in pain in patients with fibromyalgia, according to a study published in the February issue of Arthritis & Rheumatism.

Jarred Younger, PhD, from the Stanford University School of Medicine in Palo Alto, CA, and colleagues conducted a crossover study involving 31 women with fibromyalgia who were randomly assigned to a four-week placebo stage and a 12-week active phase comprising 4.5mg/day of naltrexone. Daily levels of pain were assessed.

The researchers found that baseline pain was significantly reduced in patients taking low-dose naltrexone vs. placebo (reduction of 28.8% vs. 18%). There was also significant improvement in general satisfaction with life and mood in patients taking naltrexone, although there was no improvement in fatigue or sleep. The response rate, as assessed by significant reductions in pain plus a significant reduction either fatigue or sleep problems, was significantly higher for low-dose naltrexone than placebo (32% vs. 11%). Naltrexone was as well tolerated as placebo and there were no serious side effects.

"Our replicated observation that low-dose naltrexone affects levels of pain, together with the low cost and tolerable nature of low-dose naltrexone, makes it a promising target for future investigation," Younger and colleagues conclude.

Abstract
Full Text (subscription or payment may be required)

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page